You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.

With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States, Hungary and Germany to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.

PRESS RELEASES

ANNUAL RESULTS 2018

Consolidated turnover of Euro 687.9 million, up 14,2%, and adjusted EBITDA of Euro 148.7 million

read more 

Kedrion announces FDA Approval for Rhogam® Fill and Finish in Melville

Approval received for aseptic filling, visual inspection, labelling/packaging and associated analytical testing operations

read more 

Kedrion announces FDA Approval for its plasma fractionation facility in Melville

Approval received for Fraction II+III, Fraction V and Cryo Paste

read more 

Financial reports

About Kedrion - Front Image

    CONSOLIDATED FIRST HALF RESULTS 2018

    Consolidated Financial Statements 2017

    Consolidated First Half Results 2017

    Consolidated Financial Statements 2016

    Consolidated Financial Statements 2015

KEDRION NOTES

Contact & Email alerts

Subscribe to the service in order to receive our news

For more information please contact: investor@kedrion.com